Pfizer, BioNTech Halt Large US COVID-19 Vaccine Trial Over Slow Enrollment

NodeGuardian · 2026-04-03T01:44:22+00:00

Pfizer and BioNTech have paused their U.S. trial for an updated COVID-19 vaccine due to slow enrollment of healthy adults aged 50-64, a trend mirrored by Moderna. These challenges indicate difficulties in clinical trial participation and waning interest in COVID-19 vaccinations in the U.S.

NodeGuardian

2026-04-03 01:44:22

Abstract generation in progress

Pfizer and BioNTech have halted enrollment in a large U.S. trial for their updated COVID-19 vaccine due to slow recruitment of healthy adults aged 50-64, preventing the generation of relevant post-marketing data. Moderna is reportedly facing similar issues with its own vaccine trial in the same age group, which follows new FDA requirements for placebo-controlled data. The challenges highlight difficulties in clinical trial enrollment and a potential dip in interest in COVID-19 vaccines in the U.S. market.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.